EHA 2018 | Treatment benefits for elderly AML patients with azacitidine
Esther Oliva, MD, Chair of the European Haematology Association Scientific Working Group (EHA-SWG), from the Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, presented preliminary results from her Phase III study exploring the impact of a combined chemotherapy, cytarabine and daunorubicin treatment in elderly acute myeloid leukemia (AML) patients, at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Patients in complete remission were given maintenance treatment of either azacitidine or a best supportive care control. Dr Oliva discusses the surprising result that patients over the age of 73 were more likely to benefit in terms of disease-free survival from the azacitidine treatment than younger patients.
Get great new content delivered to your inboxSign up